S 765/HR 1526: Reducing Hereditary Cancer Act of 2023- provide hereditary cancer genetic testing
Increasing access to telehealth
S 2016/HR 4189: CONNECT for Health Act- expands access to telehealth services
Medicare physician payment reforms
HR 2474: Strengthening Medicare for Patients and Providers Act- physician reimbursement
HR 5013: Value in Health Care Act of 2023 - provides a multi-year commitment to reforming care delivery by extending MACRA's 5 percent advanced APM incentives for an additional two years.
S 3503: Value in Health Care Act of 2023 - A bill to direct the Secretary of Health and Human Services to revise certain regulations in relation to the Medicare shared savings program and other alternative payment arrangements to encourage participation in such program, and for other purposes
HR 6371: Provider Reimbursement Stability Act of 2023 - To provide for certain adjustments to the physician fee schedule under the Medicare program.
H.R. 6369: To amend title XVIII of the Social Security Act to extend incentive payments for participation in eligible alternative payment models - Extend incentive payments for participation in alternative payment models
HR 3674: Providing Relief and Stability for Medicare Patients Act of 2023 - increase the nonfacility practice expense relative value units for specified services furnished under the Medicare program
Reducing burdens caused by prior authorization requirements
HR 4968: GOLD CARD Act of 2023 - exempt qualifying providers from prior authorization requirements under Medicare Advantage plans
S 2372/HR 4758: Accelerating Kids' Access to Care Act - improve childrens access to needed out-of-state health care by streamlining Medicaid provider screening and enrollment processes.
HR 6364: Medicare Telehealth Privacy Act of 2023 - To amend title XVIII of the Social Security Act to maintain certain telehealth flexibilities relating to provider privacy under the Medicare program
S 2764/HR 5391: Protecting Patient Access to Cancer and Complex Therapies Act of 2023 - ensures patients will be able to access critical medications and providers will be reimbursed fairly, unaffected by drug pricing negotiations between Medicare and drug manufacturers.
S 2345/HR 4714: Pediatricians Accelerate Childhood Therapies Act of 2023 - requires the National Institutes of Health (NIH) to make awards to support early-career pediatric researchers. It also provides statutory authority for the NIH Pediatric Research Consortium to coordinate pediatric research across national health research institutions.
S 3967/HR 7623: Telehealth Modernization Act of 2024 - permanently extends telehealth flexibilities for Medicare beneficiaries.
S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan
S 1375/HR 830: HELP Copays Act- copay accumulator programs
Addressing Pharmacy Benefit Managers
S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs
S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice
Palliative care
S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship
S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs
HR 3633: PREVENT HPV Cancers Act of 2023
S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research
Addressing healthcare workforce shortages
Increasing diversity in clinical trials
Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile
S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks
HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients
HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes.
HR 3008: Drug Shortage Prevention Act of 2023 - Require manufacturers to provide initial notification to the FDA no more than 48 hours after a sustained increase in demand for a drug
S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain
S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions
HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them.
HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider.
HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes.
Support banning the sale of menthol cigarettes and flavored cigars
Oppose S 107: Traditional Cigar Manufacturing and Jobs Act
Support HR 4775: Helping Tobacco Users Quit Act - provide coverage of comprehensive tobacco cessation services
FY 2024 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).
Duration: January 1, 2020
to
present
General Issues: Medicare/Medicaid , Health Issues , Tobacco , Budget/Appropriations
Spending: about $2,562,219 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
ASSOCIATION FOR CLINICAL ONCOLOGY amended a lobbying report for in-house lobbying in Q12024 on May 3
Original Filing: 301578024.xml
Lobbying Issues
S 765/HR 1526: Reducing Hereditary Cancer Act of 2023- provide hereditary cancer genetic testing
Increasing access to telehealth
S 2016/HR 4189: CONNECT for Health Act- expands access to telehealth services
Medicare physician payment reforms
HR 2474: Strengthening Medicare for Patients and Providers Act- physician reimbursement
HR 5013: Value in Health Care Act of 2023 - provides a multi-year commitment to reforming care delivery by extending MACRA's 5 percent advanced APM incentives for an additional two years.
S 3503: Value in Health Care Act of 2023 - A bill to direct the Secretary of Health and Human Services to revise certain regulations in relation to the Medicare shared savings program and other alternative payment arrangements to encourage participation in such program, and for other purposes
HR 6371: Provider Reimbursement Stability Act of 2023 - To provide for certain adjustments to the physician fee schedule under the Medicare program.
H.R. 6369: To amend title XVIII of the Social Security Act to extend incentive payments for participation in eligible alternative payment models - Extend incentive payments for participation in alternative payment models
HR 3674: Providing Relief and Stability for Medicare Patients Act of 2023 - increase the nonfacility practice expense relative value units for specified services furnished under the Medicare program
Reducing burdens caused by prior authorization requirements
HR 4968: GOLD CARD Act of 2023 - exempt qualifying providers from prior authorization requirements under Medicare Advantage plans
S 2372/HR 4758: Accelerating Kids' Access to Care Act - improve childrens access to needed out-of-state health care by streamlining Medicaid provider screening and enrollment processes.
HR 6364: Medicare Telehealth Privacy Act of 2023 - To amend title XVIII of the Social Security Act to maintain certain telehealth flexibilities relating to provider privacy under the Medicare program
S 2764/HR 5391: Protecting Patient Access to Cancer and Complex Therapies Act of 2023 - ensures patients will be able to access critical medications and providers will be reimbursed fairly, unaffected by drug pricing negotiations between Medicare and drug manufacturers.
S 2345/HR 4714: Pediatricians Accelerate Childhood Therapies Act of 2023 - requires the National Institutes of Health (NIH) to make awards to support early-career pediatric researchers. It also provides statutory authority for the NIH Pediatric Research Consortium to coordinate pediatric research across national health research institutions.
S 3967/HR 7623: Telehealth Modernization Act of 2024 - permanently extends telehealth flexibilities for Medicare beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan
S 1375/HR 830: HELP Copays Act- copay accumulator programs
Addressing Pharmacy Benefit Managers
S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs
S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice
Palliative care
S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship
S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs
HR 3633: PREVENT HPV Cancers Act of 2023
S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research
Addressing healthcare workforce shortages
Increasing diversity in clinical trials
Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile
S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks
HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients
HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes.
HR 3008: Drug Shortage Prevention Act of 2023 - Require manufacturers to provide initial notification to the FDA no more than 48 hours after a sustained increase in demand for a drug
S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain
S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions
HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them.
HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider.
HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Support banning the sale of menthol cigarettes and flavored cigars
Oppose S 107: Traditional Cigar Manufacturing and Jobs Act
Support HR 4775: Helping Tobacco Users Quit Act - provide coverage of comprehensive tobacco cessation services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2024 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2024
In Q1, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on April 22.
Original Filing: 301574643.xml
Lobbying Issues
S 765/HR 1526: Reducing Hereditary Cancer Act of 2023- provide hereditary cancer genetic testing
Increasing access to telehealth
S 2016/HR 4189: CONNECT for Health Act- expands access to telehealth services
Medicare physician payment reforms
HR 2474: Strengthening Medicare for Patients and Providers Act- physician reimbursement
HR 5013: Value in Health Care Act of 2023 - provides a multi-year commitment to reforming care delivery by extending MACRA's 5 percent advanced APM incentives for an additional two years.
S 3503: Value in Health Care Act of 2023 - A bill to direct the Secretary of Health and Human Services to revise certain regulations in relation to the Medicare shared savings program and other alternative payment arrangements to encourage participation in such program, and for other purposes
HR 6371: Provider Reimbursement Stability Act of 2023 - To provide for certain adjustments to the physician fee schedule under the Medicare program.
H.R. 6369: To amend title XVIII of the Social Security Act to extend incentive payments for participation in eligible alternative payment models - Extend incentive payments for participation in alternative payment models
HR 3674: Providing Relief and Stability for Medicare Patients Act of 2023 - increase the nonfacility practice expense relative value units for specified services furnished under the Medicare program
Reducing burdens caused by prior authorization requirements
HR 4968: GOLD CARD Act of 2023 - exempt qualifying providers from prior authorization requirements under Medicare Advantage plans
S 2372/HR 4758: Accelerating Kids' Access to Care Act - improve childrens access to needed out-of-state health care by streamlining Medicaid provider screening and enrollment processes.
HR 6364: Medicare Telehealth Privacy Act of 2023 - To amend title XVIII of the Social Security Act to maintain certain telehealth flexibilities relating to provider privacy under the Medicare program
S 2764/HR 5391: Protecting Patient Access to Cancer and Complex Therapies Act of 2023 - ensures patients will be able to access critical medications and providers will be reimbursed fairly, unaffected by drug pricing negotiations between Medicare and drug manufacturers.
S 2345/HR 4714: Pediatricians Accelerate Childhood Therapies Act of 2023 - requires the National Institutes of Health (NIH) to make awards to support early-career pediatric researchers. It also provides statutory authority for the NIH Pediatric Research Consortium to coordinate pediatric research across national health research institutions.
S 3967/HR 7623: Telehealth Modernization Act of 2024 - permanently extends telehealth flexibilities for Medicare beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan
S 1375/HR 830: HELP Copays Act- copay accumulator programs
Addressing Pharmacy Benefit Managers
S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs
S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice
Palliative care
S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship
S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs
HR 3633: PREVENT HPV Cancers Act of 2023
S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research
Addressing healthcare workforce shortages
Increasing diversity in clinical trials
Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile
S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks
HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients
HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes.
HR 3008: Drug Shortage Prevention Act of 2023 - Require manufacturers to provide initial notification to the FDA no more than 48 hours after a sustained increase in demand for a drug
S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain
S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions
HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them.
HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider.
HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Support banning the sale of menthol cigarettes and flavored cigars
Oppose S 107: Traditional Cigar Manufacturing and Jobs Act
Support HR 4775: Helping Tobacco Users Quit Act - provide coverage of comprehensive tobacco cessation services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2024 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2023
In Q4, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on Jan. 19.
Original Filing: 301530003.xml
Lobbying Issues
S 765/HR 1526: Reducing Hereditary Cancer Act of 2023- provide hereditary cancer genetic testing
Increasing access to telehealth
S 2016/HR 4189: CONNECT for Health Act- expands access to telehealth services
Medicare physician payment reforms
HR 2474: Strengthening Medicare for Patients and Providers Act- physician reimbursement
HR 5013: Value in Health Care Act of 2023 - provides a multi-year commitment to reforming care delivery by extending MACRA's 5 percent advanced APM incentives for an additional two years.
S 3503: Value in Health Care Act of 2023 - A bill to direct the Secretary of Health and Human Services to revise certain regulations in relation to the Medicare shared savings program and other alternative payment arrangements to encourage participation in such program, and for other purposes
HR 6371: Provider Reimbursement Stability Act of 2023 - To provide for certain adjustments to the physician fee schedule under the Medicare program.
H.R. 6369: To amend title XVIII of the Social Security Act to extend incentive payments for participation in eligible alternative payment models - Extend incentive payments for participation in alternative payment models
HR 3674: Providing Relief and Stability for Medicare Patients Act of 2023 - increase the nonfacility practice expense relative value units for specified services furnished under the Medicare program
Reducing burdens caused by prior authorization requirements
HR 4968: GOLD CARD Act of 2023 - exempt qualifying providers from prior authorization requirements under Medicare Advantage plans
S 2372/HR 4758: Accelerating Kids' Access to Care Act - improve childrens access to needed out-of-state health care by streamlining Medicaid provider screening and enrollment processes.
HR 6364: Medicare Telehealth Privacy Act of 2023 - To amend title XVIII of the Social Security Act to maintain certain telehealth flexibilities relating to provider privacy under the Medicare program
S 2764/HR 5391: Protecting Patient Access to Cancer and Complex Therapies Act of 2023 - ensures patients will be able to access critical medications and providers will be reimbursed fairly, unaffected by drug pricing negotiations between Medicare and drug manufacturers.
S 2345/HR 4714: Pediatricians Accelerate Childhood Therapies Act of 2023 - requires the National Institutes of Health (NIH) to make awards to support early-career pediatric researchers. It also provides statutory authority for the NIH Pediatric Research Consortium to coordinate pediatric research across national health research institutions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan
S 1375/HR 830: HELP Copays Act- copay accumulator programs
Addressing Pharmacy Benefit Managers
S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs
S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice
Palliative care
S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship
S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs
HR 3633: PREVENT HPV Cancers Act of 2023
S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research
Addressing healthcare workforce shortages
Increasing diversity in clinical trials
Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile
S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks
HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients
HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes.
HR 3008: Drug Shortage Prevention Act of 2023 - Require manufacturers to provide initial notification to the FDA no more than 48 hours after a sustained increase in demand for a drug
S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain
S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions
HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them.
HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider.
HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes
PN 649: Monica M. Bertagnolli, Department of Health and Human Services - Nomination of Monica Bertagnolli for the Director of the National Institutes of Health
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Support banning the sale of menthol cigarettes and flavored cigars
Oppose S 107: Traditional Cigar Manufacturing and Jobs Act
Support HR 4775: Helping Tobacco Users Quit Act - provide coverage of comprehensive tobacco cessation services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2024 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2023
In Q3, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on Oct. 19, 2023.
Original Filing: 301506032.xml
Lobbying Issues
S 765/HR 1526: Reducing Hereditary Cancer Act of 2023- provide hereditary cancer genetic testing
Increasing access to telehealth
S 2016/HR 4189: CONNECT for Health Act- expands access to telehealth services
Medicare physician payment reforms
HR 2474: Strengthening Medicare for Patients and Providers Act- physician reimbursement
HR 5013: Value in Health Care Act of 2023 - provides a multi-year commitment to reforming care delivery by extending MACRA's 5 percent advanced APM incentives for an additional two years.
Reducing burdens caused by prior authorization requirements
HR 4968: GOLD CARD Act of 2023 - exempt qualifying providers from prior authorization requirements under Medicare Advantage plans
S 2372/HR 4758: Accelerating Kids' Access to Care Act - improve childrens access to needed out-of-state health care by streamlining Medicaid provider screening and enrollment processes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan
S 1375/HR 830: HELP Copays Act- copay accumulator programs
Addressing Pharmacy Benefit Managers
S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs
S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice
Palliative care
S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship
S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs
HR 3633: PREVENT HPV Cancers Act of 2023
S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research
Addressing healthcare workforce shortages
Increasing diversity in clinical trials
Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile
S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks
HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients
HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes.
HR 3008: Drug Shortage Prevention Act of 2023 - Require manufacturers to provide initial notification to the FDA no more than 48 hours after a sustained increase in demand for a drug
S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain
S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Support banning the sale of menthol cigarettes and flavored cigars
Oppose S 107: Traditional Cigar Manufacturing and Jobs Act
Support HR 4775: Helping Tobacco Users Quit Act - provide coverage of comprehensive tobacco cessation services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2024 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2023
In Q2, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on July 18, 2023.
Original Filing: 301478891.xml
Lobbying Issues
S 765/HR 1526: Reducing Hereditary Cancer Act of 2023- provide hereditary cancer genetic testing
S 2016/HR 4189: CONNECT for Health Act- expands access to telehealth services
Increasing access to telehealth
HR 2474: Strengthening Medicare for Patients and Providers Act- physician reimbursement
Medicare physician payment reforms
Reducing burdens caused by prior authorization requirements
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
HR 830/S 1375: HELP Copays Act- copay accumulator programs
S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs
S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice
Palliative care
S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship
S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs
HR 3633: PREVENT HPV Cancers Act of 2023
S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research
Addressing healthcare workforce shortages
Increasing diversity in clinical trials
S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks
Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile
Regulating Laboratory Developed Tests (LDTs) and in vitro diagnostic tests (IVDs)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Oppose S 107: Traditional Cigar Manufacturing and Jobs Act
Support banning the sale of menthol cigarettes and flavored cigars
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2024 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2023
In Q1, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on April 17, 2023.
Original Filing: 301453537.xml
Lobbying Issues
S 765/HR 1526- Reducing Hereditary Cancer Act of 2023- provide hereditary cancer genetic testing
Increasing access to telehealth
Reducing burdens caused by prior authorization requirements
Medicare physician payment reforms
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 652- Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
HR 830- HELP Copays Act- copay accumulator programs
S 127- Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs
S 79- Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
Addressing healthcare workforce shortages
Increasing diversity in clinical trials
Mitigating drug shortages
Palliative care
Regulating Laboratory Developed Tests (LDTs) and in vitro diagnostic tests (IVDs)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Oppose S 107- Traditional Cigar Manufacturing and Jobs Act
Support banning the sale of menthol cigarettes and flavored cigars
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2024 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2022
In Q4, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301432674.xml
Lobbying Issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946/S 1873- Multi Cancer Early Detection Coverage and Screening Act - provide for Medicare coverage of multi-cancer early detection screening tests
HR 1577/S 596 - Treat and Reduce Obesity Act of 2021 - expands Medicare coverage of intensive behavioral therapy for obesity
HR 2347/S 2691 - Strengthening the Vaccines for Children Program Act of 2021 - ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program
S 1287 - REFUND Act of 2021 - provide refunds for certain single dose vial drugs
HR 2903/S 1512- CONNECT for Health Act of 2021 - expand access to telehealth services
HR 3173/S 3018- Improving Seniors Timely Access to Care Act of 2021- establishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
HR 3447 - Permanency for Audio-Only Telehealth Act- expand accessibility to certain telehealth services under Medicare
HR 4110/S 3656- Reducing Hereditary Cancer Act- provide hereditary cancer genetic testing
HR 3089/S 1544- Accelerating Kids' Access to Care Act- streamline enrollment under the Medicaid program of certain providers across State lines
HR 1978/S 912- Protecting Seniors Through Immunization Act of 2021- improve Medicare coverage of vaccinations
HR 7995- GOLD CARD Act of 2022- exempts qualifying physicians from prior authorization requirements in Medicare Advantage plans
HR 5377- Cancer Patient Equity Act of 2021- provides coverage of cancer diagnostic and laboratory tests under Medicare, Medicaid, and CHIP
Drug pricing- Inflation Reduction Act
HR 8800- Supporting Medicare Providers Act of 2022- Medicare reimbursement
HR 8487- Improving Seniors Timely Access to Care Act of 2022- establishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
Omnibus: PAYGO, sequestration, HR 8800, APM bonus
HR 2410/S 5117- Medicare & You Handbook Improvement Act of 2021- requires the inclusion of information on prior authorization requirements and other utilization management techniques in the Medicare & You annual notice.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
HR 1550 - PREVENT HPV Cancers Act of 2021
HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications
HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity
HR 5801- HELP Copays Act- copay accumulator programs
S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH
HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials
HR 6584- DEPICT Act- access to clinical trials
HR 6000- Cures 2.0
HR 5963/S 3611- Provider Relief Fund Improvement Act- extends deadlines, expands the uses of, and makes other changes pertaining to the Provider Relief Fund
HR 4450/S 2352- Access to Infertility Treatment and Care Act- requires private insurance to cover fertility preservation services
ARPA-H
FDA User Fee Agreement policy riders: increasing diversity in clinical trials, improvements to accelerated approval pathway, expanded use of real world data, and in vitro clinical tests
HR 7630/S 4120- Childhood Cancer STAR Reauthorization Act of 2022- reauthorizes the STAR Act through FY2028
S 4293- Pharmacy Benefit Manager Transparency Act of 2022- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs
S 4430- Interagency Patent Coordination and Improvement Act of 2022- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
S 5295/HR 9565- Comprehensive Cancer Survivorship Act- addresses the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment
HR 4128/S 2209- VALID Act of 2021- requires FDA to regulate in vitro clinical tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
support HR 2125 - Quit Because of COVID-19 Act - provide coverage of comprehensive tobacco cessation services under such titles
funding for the Office of Smoking and Health
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
S 2187 - National Biomedical Research Act- establishes Biomedical Innovation Fund
H.R. 5394- Meaningful Access to Federal Health Plan Claims Data Act of 2021 -ensures meaningful access to claims data by clinician-led clinical data registries
HR 3773/S 1357- PACT Act of 2021- requires the NIH to support early career pediatric researchers
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2022
In Q3, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on Oct. 19, 2022.
Original Filing: 301409867.xml
Lobbying Issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946/S 1873- Multi Cancer Early Detection Coverage and Screening Act - provide for Medicare coverage of multi-cancer early detection screening tests
HR 1577/S 596 - Treat and Reduce Obesity Act of 2021 - expands Medicare coverage of intensive behavioral therapy for obesity
HR 2347/S 2691 - Strengthening the Vaccines for Children Program Act of 2021 - ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program
S 1287 - REFUND Act of 2021 - provide refunds for certain single dose vial drugs
HR 2903/S 1512- CONNECT for Health Act of 2021 - expand access to telehealth services
HR 3173/S 3018- Improving Seniors Timely Access to Care Act of 2021- stablishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
HR 3447 - Permanency for Audio-Only Telehealth Act- expand accessibility to certain telehealth services under Medicare
HR 4110/S 3656- Reducing Hereditary Cancer Act- provide hereditary cancer genetic testing
HR 3089/S 1544- Accelerating Kids' Access to Care Act- streamline enrollment under the Medicaid program of certain providers across State lines
HR 1978/S 912- Protecting Seniors Through Immunization Act of 2021- improve Medicare coverage of vaccinations
HR 7995- GOLD CARD Act of 2022- exempts qualifying physicians from prior authorization requirements in Medicare Advantage plans
HR 5377- Cancer Patient Equity Act of 2021- provides coverage of cancer diagnostic and laboratory tests under Medicare, Medicaid, and CHIP
Drug pricing- Inflation Reduction Act
HR 8800- Supporting Medicare Providers Act of 2022- Medicare reimbursement
HR 8487- Improving Seniors Timely Access to Care Act of 2022- establishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
HR 1550 - PREVENT HPV Cancers Act of 2021
HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications
HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity
HR 5801- HELP Copays Act- copay accumulator programs
S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH
HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials
HR 6584- DEPICT Act- access to clinical trials
HR 6000- Cures 2.0
HR 5963/S 3611- Provider Relief Fund Improvement Act- extends deadlines, expands the uses of, and makes other changes pertaining to the Provider Relief Fund
HR 4450/S 2352- Access to Infertility Treatment and Care Act- requires private insurance to cover fertility preservation services
ARPA-H
FDA User Fee Agreement policy riders: increasing diversity in clinical trials, improvements to accelerated approval pathway, expanded use of real world data, and in vitro clinical tests
HR 7630/S 4120- Childhood Cancer STAR Reauthorization Act of 2022- reauthorizes the STAR Act through FY2028
S 4293- Pharmacy Benefit Manager Transparency Act of 2022- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs
S 4430- Interagency Patent Coordination and Improvement Act of 2022- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
support HR 2125 - Quit Because of COVID-19 Act - provide coverage of comprehensive tobacco cessation services under such titles
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
S 2187 - National Biomedical Research Act- establishes Biomedical Innovation Fund
H.R. 5394- Meaningful Access to Federal Health Plan Claims Data Act of 2021 -ensures meaningful access to claims data by clinician-led clinical data registries
HR 3773/S 1357- PACT Act of 2021- requires the NIH to support early career pediatric researchers
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2022
In Q2, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301389776.xml
Lobbying Issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946/S 1873- Multi Cancer Early Detection Coverage and Screening Act - provide for Medicare coverage of multi-cancer early detection screening tests
HR 1577/S 596 - Treat and Reduce Obesity Act of 2021 - expands Medicare coverage of intensive behavioral therapy for obesity
HR 2347/S 2691 - Strengthening the Vaccines for Children Program Act of 2021 - ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program
S 1287 - REFUND Act of 2021 - provide refunds for certain single dose vial drugs
HR 2903/S 1512- CONNECT for Health Act of 2021 - expand access to telehealth services
HR 3173/S 3018- Improving Seniors Timely Access to Care Act of 2021- stablishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
HR 3447 - Permanency for Audio-Only Telehealth Act- expand accessibility to certain telehealth services under Medicare
HR 4110/S 3656- Reducing Hereditary Cancer Act- provide hereditary cancer genetic testing
HR 3089/S 1544- Accelerating Kids' Access to Care Act- streamline enrollment under the Medicaid program of certain providers across State lines
HR 1978/S 912- Protecting Seniors Through Immunization Act of 2021- improve Medicare coverage of vaccinations
HR 7995- GOLD CARD Act of 2022- exempts qualifying physicians from prior authorization requirements in Medicare Advantage plans
HR 5377- Cancer Patient Equity Act of 2021- provides coverage of cancer diagnostic and laboratory tests under Medicare, Medicaid, and CHIP
Drug pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
HR 1550 - PREVENT HPV Cancers Act of 2021
HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications
HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity
HR 5801- HELP Copays Act- copay accumulator programs
S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH
HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials
HR 6584- DEPICT Act- access to clinical trials
HR 6000- Cures 2.0
HR 5963/S 3611- Provider Relief Fund Improvement Act- extends deadlines, expands the uses of, and makes other changes pertaining to the Provider Relief Fund
HR 4450/S 2352- Access to Infertility Treatment and Care Act- requires private insurance to cover fertility preservation services
ARPA-H
FDA User Fee Agreement Reauthorization
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
support HR 2125 - Quit Because of COVID-19 Act - provide coverage of comprehensive tobacco cessation services under such titles
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
S 2187 - National Biomedical Research Act- establishes Biomedical Innovation Fund
H.R. 5394- Meaningful Access to Federal Health Plan Claims Data Act of 2021 -ensures meaningful access to claims data by clinician-led clinical data registries
HR 3773/S 1357- PACT Act of 2021- requires the NIH to support early career pediatric researchers
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2022
In Q1, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on April 19, 2022.
Original Filing: 301363161.xml
Lobbying Issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946/S 1873- Multi Cancer Early Detection Coverage and Screening Act - provide for Medicare coverage of multi-cancer early detection screening tests
HR 1577/S 596 - Treat and Reduce Obesity Act of 2021 - expands Medicare coverage of intensive behavioral therapy for obesity
HR 2347/S 2691 - Strengthening the Vaccines for Children Program Act of 2021 - ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program
S 1287 - REFUND Act of 2021 - provide refunds for certain single dose vial drugs
HR 2903/S 1512- CONNECT for Health Act of 2021 - expand access to telehealth services
HR 3173/S 3018- Improving Seniors Timely Access to Care Act of 2021- stablishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
HR 3447 - Permanency for Audio-Only Telehealth Act- expand accessibility to certain telehealth services under Medicare
HR 4110/S 3656- Reducing Hereditary Cancer Act- provide hereditary cancer genetic testing
HR 3089/S 1544- Accelerating Kids' Access to Care Act- streamline enrollment under the Medicaid program of certain providers across State lines
HR 1978/S 912- Protecting Seniors Through Immunization Act of 2021- improve Medicare coverage of vaccinations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
HR 1550 - PREVENT HPV Cancers Act of 2021
HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications
S 610/HR 1667- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals
HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity
HR 5801- HELP Copays Act- copay accumulator programs
S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH
HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials
HR 6584- DEPICT Act- access to clinical trials
HR 6000- Cures 2.0
ARPA-H
FDA User Fee Agreement Reauthorization
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
support HR 2125 - Quit Because of COVID-19 Act - provide coverage of comprehensive tobacco cessation services under such titles
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
S 2187 - National Biomedical Research Act-
H.R. 5394- Meaningful Access to Federal Health Plan Claims Data Act of 2021 -ensures meaningful access to claims data by clinician-led clinical data registries
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2021
ASSOCIATION FOR CLINICAL ONCOLOGY amended a lobbying report for in-house lobbying in Q42021 on Feb. 11, 2022
Original Filing: 301341208.xml
Lobbying Issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946/S 1873- Multi Cancer Early Detection Coverage and Screening Act - provide for Medicare coverage of multi-cancer early detection screening tests
HR 1577/S 596 - Treat and Reduce Obesity Act of 2021 - expands Medicare coverage of intensive behavioral therapy for obesity
HR 2347/S 2691 - Strengthening the Vaccines for Children Program Act of 2021 - ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program
S 1287 - REFUND Act of 2021 - provide refunds for certain single dose vial drugs
HR 2903/S 1512- CONNECT for Health Act of 2021 - expand access to telehealth services
HR 3173/S 3018- Improving Seniors Timely Access to Care Act of 2021- stablishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
HR 3447 - Permanency for Audio-Only Telehealth Act- expand accessibility to certain telehealth services under Medicare
HR 4110- Reducing Hereditary Cancer Act- provide hereditary cancer genetic testing
HR 3089/S 1544- Accelerating Kids' Access to Care Act- streamline enrollment under the Medicaid program of certain providers across State lines
HR 1978/S 912- Protecting Seniors Through Immunization Act of 2021- improve Medicare coverage of vaccinations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
HR 1550 - PREVENT HPV Cancers Act of 2021
HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications
S 610- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals
HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity
HR 5801- HELP Copays Act- copay accumulator programs
S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH
HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
support HR 2125 - Quit Because of COVID-19 Act - provide coverage of comprehensive tobacco cessation services under such titles
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
S 2187 - National Biomedical Research Act-
H.R. 5394- Meaningful Access to Federal Health Plan Claims Data Act of 2021 -ensures meaningful access to claims data by clinician-led clinical data registries
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2021
In Q4, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301335533.xml
Lobbying Issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946/S 1873- Multi Cancer Early Detection Coverage and Screening Act - provide for Medicare coverage of multi-cancer early detection screening tests
HR 1577/S 596 - Treat and Reduce Obesity Act of 2021 - expands Medicare coverage of intensive behavioral therapy for obesity
HR 2347/S 2691 - Strengthening the Vaccines for Children Program Act of 2021 - ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program
S 1287 - REFUND Act of 2021 - provide refunds for certain single dose vial drugs
HR 2903/S 1512- CONNECT for Health Act of 2021 - expand access to telehealth services
HR 3173/S 3018- Improving Seniors Timely Access to Care Act of 2021- stablishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
HR 3447 - Permanency for Audio-Only Telehealth Act- expand accessibility to certain telehealth services under Medicare
HR 4110- Reducing Hereditary Cancer Act- provide hereditary cancer genetic testing
HR 3089/S 1544- Accelerating Kids' Access to Care Act- streamline enrollment under the Medicaid program of certain providers across State lines
HR 1978/S 912- Protecting Seniors Through Immunization Act of 2021- improve Medicare coverage of vaccinations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
HR 1550 - PREVENT HPV Cancers Act of 2021
HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications
S 610- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals
HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity
HR 5801- HELP Copays Act- copay accumulator programs
S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH
HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
support HR 2125 - Quit Because of COVID-19 Act - provide coverage of comprehensive tobacco cessation services under such titles
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
S 2187 - National Biomedical Research Act-
H.R. 5394- Meaningful Access to Federal Health Plan Claims Data Act of 2021 -ensures meaningful access to claims data by clinician-led clinical data registries
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2021
In Q3, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301311133.xml
Lobbying Issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946/S 1873- Multi Cancer Early Detection Coverage and Screening Act - provide for Medicare coverage of multi-cancer early detection screening tests
HR 1577/S 596 - Treat and Reduce Obesity Act of 2021 - expands Medicare coverage of intensive behavioral therapy for obesity
HR 2347/S 2691 - Strengthening the Vaccines for Children Program Act of 2021 - ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program
S 1287 - REFUND Act of 2021 - provide refunds for certain single dose vial drugs
HR 2903/S 1512- CONNECT for Health Act of 2021 - expand access to telehealth services
HR 3173- Improving Seniors Timely Access to Care Act of 2021- stablishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
HR 3447 - Permanency for Audio-Only Telehealth Act- expand accessibility to certain telehealth services under Medicare
HR 4110- Reducing Hereditary Cancer Act- provide hereditary cancer genetic testing
HR 3089/S 1544- Accelerating Kids' Access to Care Act- streamline enrollment under the Medicaid program of certain providers across State lines
HR 1978/S 912- Protecting Seniors Through Immunization Act of 2021- improve Medicare coverage of vaccinations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
H.R. 1550 - PREVENT HPV Cancers Act of 2021
HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications
S 610- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals
HR 4385- Cancer Drug Parity Act of 2021- oral parity
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
support HR 2125 - Quit Because of COVID-19 Act - provide coverage of comprehensive tobacco cessation services under such titles
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
S 2187 - National Biomedical Research Act-
H.R. 5394- Meaningful Access to Federal Health Plan Claims Data Act of 2021 -ensures meaningful access to claims data by clinician-led clinical data registries
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
In Q2, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on July 21, 2021.
Original Filing: 301292284.xml
Lobbying Issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946/S 1873- Multi Cancer Early Detection Coverage and Screening Act - provide for Medicare coverage of multi-cancer early detection screening tests
HR 1577/S 596 - Treat and Reduce Obesity Act of 2021 - expands Medicare coverage of intensive behavioral therapy for obesity
HR 2347 - Strengthening the Vaccines for Children Program Act of 2021 - ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program
S 1287 - REFUND Act of 2021 - provide refunds for certain single dose vial drugs
HR 2903/S 1512- CONNECT for Health Act of 2021 - expand access to telehealth services
HR 3173- Improving Seniors Timely Access to Care Act of 2021- stablishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
HR 3447 - Permanency for Audio-Only Telehealth Act- expand accessibility to certain telehealth services under Medicare
HR 4110- Reducing Hereditary Cancer Act- provide hereditary cancer genetic testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
H.R. 1550 - PREVENT HPV Cancers Act of 2021
HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications
S 610- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
support HR 2125 - Quit Because of COVID-19 Act - provide coverage of comprehensive tobacco cessation services under such titles
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
S 2187 - National Biomedical Research Act-
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2021
In Q1, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on April 21, 2021.
Original Filing: 301268405.xml
Lobbying Issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946 Multi Cancer Early Detection Coverage and Screening Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
H.R. 1550 - PREVENT HPV Cancers Act of 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2020
In Q4, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on Jan. 29, 2021.
Original Filing: 301247185.xml
Lobbying Issues
HR 913/S 4742 - CLINICAL TREATMENT Act, Medicaid clinical trials coverage
HR 3107/S 5044 - Improving Seniors' Timely Access to Care Act, Prior authorization in Medicare Advantage
Repeal of the Medicare sequester
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Cancer Drug Parity Act (HR 1740/S 741)
Safe Step Act (HR 2279/S 2546)
Mitigating Emergency Drug Shortages Act (S 2723/HR 6080)
Palliative Care Hospice Education and Training Act (HR 647/S 2080)
The Prescription Drug Pricing Reduction Act (S 2543)
Access to Infertility Treatment and Care Act (HR 2308/S 1461)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act - HR 2111/S 1048
Quit Because of COVID Act - HR 7286
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for the National Institutes of Health, the National Cancer Institute, and the Food & Drug Administration including funding for the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Gabriella Miller Kids First Research Act 2.0 - HR 6556
Research Investments to Spark the Economy Act - HR 7308
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2020
In Q3, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301222333.xml
Lobbying Issues
HR 913/S 4742 - CLINICAL TREATMENT Act
HR 3107 - Improving Seniors' Timely Access to Care Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Cancer Drug Parity Act (HR 1740/S 741)
Safe Step Act (HR 2279/S 2546)
Mitigating Emergency Drug Shortages Act (S 2723/HR 6080)
Palliative Care Hospice Education and Training Act (HR 647/S 2080)
The Prescription Drug Pricing Reduction Act (S 2543)
Access to Infertility Treatment and Care Act (HR 2308/S 1461)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act - HR 2111/S 1048
Quit Because of COVID Act - HR 7286
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for the National Institutes of Health, the National Cancer Institute, and the Food & Drug Administration including funding for the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Gabriella Miller Kids First Research Act 2.0 - HR 6556
Research Investments to Spark the Economy Act - HR 7308
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301200219.xml
Lobbying Issues
HR 913 - CLINICAL TREATMENT Act
HR 3107 - Improving Seniors' Timely Access to Care Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Cancer Drug Parity Act (HR 1740/S 741)
Safe Step Act (HR 2279/S 2546)
Mitigating Emergency Drug Shortages Act (S 2723/HR 6080)
Palliative Care Hospice Education and Training Act (HR 647/S 2080)
The Prescription Drug Pricing Reduction Act (S 2543)
Access to Infertility Treatment and Care Act (HR 2308/S 1461)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act - HR 2111/S 1048
Quit Because of COVID Act - HR 7286
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for the National Institutes of Health, the National Cancer Institute, and the Food & Drug Administration including funding for the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Gabriella Miller Kids First Research Act 2.0 - HR 6556
Research Investments to Spark the Economy Act - HR 7308
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
ASSOCIATION FOR CLINICAL ONCOLOGY filed a lobbying registration on April 20, 2020 for in-house lobbying efforts, effective Jan. 1, 2020.
Original Filing: 301175511.xml
Issue(s) they said they’d lobby about: Patient access to cancer care
Medicare and Medicaid reimbursement for cancer care
Funding for the National Institutes of Health, National Cancer Institute, and Food & Drug Administration
Tobacco Cessation .
1st Quarter, 2020
In Q1, ASSOCIATION FOR CLINICAL ONCOLOGY had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301179060.xml
Lobbying Issues
HR 913 - CLINICAL TREATMENT Act
HR 3107 - Improving Seniors' Timely Access to Care Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Cancer Drug Parity Act (HR 1740/S 741)
Safe Step Act (HR 2279/S 2546)
Mitigating Emergency Drug Shortages Act (S 2723/HR 6080)
Palliative Care Hospice Education and Training Act (HR 647/S 2080)
The Prescription Drug Pricing Reduction Act (S 2543)
Access to Infertility Treatment and Care Act (HR 2308/S 1461)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act - HR 2111/S 1048
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for the National Institutes of Health, the National Cancer Institute, and the Food & Drug Administration including funding for the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
ASSOCIATION FOR CLINICAL ONCOLOGY amended a lobbying report for in-house lobbying in Q12020 on April 20, 2020
Original Filing: 301179109.xml
Lobbying Issues
HR 913 - CLINICAL TREATMENT Act
HR 3107 - Improving Seniors' Timely Access to Care Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Cancer Drug Parity Act (HR 1740/S 741)
Safe Step Act (HR 2279/S 2546)
Mitigating Emergency Drug Shortages Act (S 2723/HR 6080)
Palliative Care Hospice Education and Training Act (HR 647/S 2080)
The Prescription Drug Pricing Reduction Act (S 2543)
Access to Infertility Treatment and Care Act (HR 2308/S 1461)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act - HR 2111/S 1048
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for the National Institutes of Health, the National Cancer Institute, and the Food & Drug Administration including funding for the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate